News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1โ€“36
Matches
114
Sources here
24
Companies here
1
Search results Stored financial headlines

Active search

114 matching headlines

Ticker or company: SLNMain companies and provider mentions
Clear
Latest

www.marketscreener.com Market update

Certain Options of Silence Therapeutics plc are subject to a Lock-Up Agreement Ending on 11-OCT-2026.

Certain Options of Silence Therapeutics plc are subject to a lock-up agreement that will end on October 11, 2026. This lock-up period began on August 11, 2026, and prevents company officers and directors from selling or disposing of specified securities without prior written consent from Jefferies and Morgan Stanley. The agreement covers various securities including ADSs, ordinary shares, โ€ฆ

Main company ๐Ÿ‡บ๐Ÿ‡ธ United States
Read at www.marketscreener.com
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
Just inNext headlines
seekingalpha.com Regulatory and legal Provider-linked mention ๐Ÿ‡บ๐Ÿ‡ธ United States

FDA, Duke-Margolis workshop to examine evidence standards for rare diseases

[Scientists inside a laboratory] Hinterhaus Productions The Food and Drug Administration and Duke-Margolis Institute for Health Policy will convene a public workshop this month to examine one of the most difficult questions in rare disease development: how to generate reliable evidence when the number โ€ฆ

SLN mentioned
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
BioSpace Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence Therapeutics to Participate in Three September 2026 Investor Conferences

Silence Therapeutics plc announced its participation in three investor conferences in September 2026: the Cantor Global Healthcare Conference, the H.C. Wainwright 28th Annual Global Investment Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference. Management will hold fireside chats at each event, and โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

StocksToTrade Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence Therapeutics Plc (SLN) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Silence Therapeutics Plc (SLN) stock. It shows the current stock price, recent price changes, and historical data. The article also mentions the absence of analyst ratings and earnings information for the company, while promoting trading bootcamps โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
BioXconomy Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence Therapeutics progresses rare blood cancer siRNA with positive trial results

Silence Therapeutics has announced positive Phase II trial results for divesiran, an siRNA drug designed to treat polycythemia vera (PV), a rare blood cancer. The SANRECO trial met its primary endpoint, showing an 88% response rate in patients treated with divesiran compared to 19% โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
dars.gov.et Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current Update - Annual Financial Report

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
dars.gov.et Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current Update - Quarterly Earnings

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
dars.gov.et Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current Update - Revenue Guidance Range

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
careplusvn.com Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence (SLN) Earnings Numbers in Focus: The Company Reports Its Latest Available Figures for the Current Session; Price Action: Shares Close 1.74% Lower in the Current Update - Earnings Expansion Phase

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
AllSci Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence Therapeutics completes private fund raise at USD 201.3m for divesiran trial

Silence Therapeutics has successfully completed an upsized public offering, raising approximately $201.3 million to fund the Phase III development of its lead siRNA asset, divesiran. This comes after positive Phase II data for divesiran in polycythemia vera patients. The company plans to initiate the โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
www.marketscreener.com Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional ADSs

Silence Therapeutics plc announced the closing of its upsized public offering, which included the full exercise of the underwriters' option to purchase additional American Depositary Shares (ADSs). The offering, consisting of 14,907,407 ADSs at $13.50 per ADS, generated gross proceeds of approximately $201.3 million. โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
Investing.com South Africa Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence Therapeutics closes $201.3M public offering By Investing.com

Silence Therapeutics plc (NASDAQ:SLN) has successfully closed an underwritten public offering, raising approximately $201.3 million. The offering included 14,907,407 American Depositary Shares at $13.50 per ADS, with underwriters fully exercising their option for additional shares. The gross proceeds will support the clinical-stage biotechnology company โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
Investing.com Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence Therapeutics closes $201.3M public offering

Silence Therapeutics plc (NASDAQ:SLN) has successfully closed an underwritten public offering, raising approximately $201.3 million in gross proceeds. The offering involved 14,907,407 American Depositary Shares (ADSs) priced at $13.50 per ADS, with each ADS representing three ordinary shares. This included the full exercise of โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
Stock Titan Deals and strategy Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Richard Griffiths (SLN) reports 14.39M-share beneficial stake in Silence Therapeutics

Richard Griffiths has updated his beneficial ownership in Silence Therapeutics plc, reporting a 7.97% stake, or 14,391,498 ordinary shares. This amendment (Amendment No. 11) reflects significant dilution due to an increase in the issuer's share capital and includes the sale of 5,484,320 ADSs by โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
BioPharm International Analyst action Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence Therapeutics Locks In $175 Million to Fuel siRNA Pipeline After Upsized ADS Offering

Silence Therapeutics has secured $175 million in funding through an upsized public offering of American depositary shares (ADSs), exceeding its initial target of $150 million. This capital infusion follows positive Phase 2 results for its siRNA candidate, divesiran, in treating polycythemia vera, where it โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
Stock Titan Deals and strategy Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence Therapeutics (SLN): Invus and Avicenna entities report 7.0% stake via Debbane

Invus Public Equities, L.P. and Avicenna Life Sci Master Fund LP have filed an updated ownership report for Silence Therapeutics plc (SLN). As of June 30, 2026, entities related to Invus beneficially held 6.1% of ordinary shares, and Avicenna-related entities held 0.9%, with Raymond โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
Pharmaceutical Executive Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing

This funding roundup highlights recent financial activities in the biotech sector, with Silence Therapeutics and AbCellera launching public offerings, and Beyang Therapeutics and Remepy closing oversubscribed Series A financing rounds. Silence Therapeutics priced its IPO at $13.50 per ADS, expecting to raise approximately $175 โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
FinancialContent Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence Therapeutics Plc - American Depository Share (SLN) Stock Price, News, Quote & History

This page provides detailed stock information for Silence Therapeutics Plc (SLN), including its current price, daily changes, market capitalization, and key financial metrics. It also features recent news and press releases, highlighting the company's financial announcements, clinical trial results for its RNA interference therapies, โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
TipRanks Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence Therapeutics Announces Major ADS Public Offering

Silence Therapeutics (SLN) has priced a public offering of 12,962,963 American Depositary Shares (ADS) at $13.50 each, aiming to raise approximately $164 million, with an option for an additional $24.7 million. This capital raise is intended to strengthen the company's financial position and support โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
Stock Titan Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence Therapeutics (SLN) prices $175M ADS sale at $13.50 per share

Silence Therapeutics plc announced the pricing of an underwritten public offering of 12,962,963 American Depositary Shares (ADSs) at $13.50 per ADS, expecting gross proceeds of approximately $175 million. The company has granted underwriters a 30-day option to purchase an additional 1,944,444 ADSs. The offering โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
TradingView Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence Therapeutics Prices 12.96M ADS Offering at $13.50; Estimated Net Proceeds $164M

Silence Therapeutics has announced a public offering of 12,962,963 American Depositary Shares (ADS) at $13.50 per share, aiming to raise approximately $164.0 million in net proceeds. Underwriters, including Jefferies and Morgan Stanley, have a 30-day option to purchase an additional 1,944,444 ADSs, which could โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
AllSci Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence upsizes USD 175m offering after divesiran Phase II win

Silence Therapeutics plc announced an upsized public offering, raising $175 million to fund the Phase III development of its lead siRNA asset, divesiran. This follows positive Phase II data for divesiran in polycythemia vera, showing an 88% clinical response rate. The company also has โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026
seekingalpha.com Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Silence Therapeutics prices upsized $175M ADS offering at $13.50 each

* Silence Therapeutics (SLN [https://seekingalpha.com/symbol/SLN]) priced an upsized underwritten public offering of 12.96M ADSs at $13.50 each, raising ~$175M in gross proceeds. * The underwriters have a 30-day option to purchase up to an additional 1.94M ADSs at the offering price. * The offering โ€ฆ

SLN main company
Sharemaestro market context Trend signal active 52 weeks +51.7% SLN stored weekly price path from 17 Oct 2025 to 9 Oct 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context